Citigroup Maintains Buy on Rigel Pharmaceuticals, Raises Price Target to $81
Benzinga Newsdesk 5 months ago
NewsPrice TargetAnalyst Ratings
Citigroup analyst Yigal Nochomovitz maintains Rigel Pharmaceuticals (NASDAQ:RIGL) with a Buy and raises the price target from $69 to $81.
Citigroup analyst Yigal Nochomovitz maintains Rigel Pharmaceuticals (NASDAQ:RIGL) with a Buy and raises the price target from $69 to $81.